Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:HEXO CVE:MPH NASDAQ:VIR NYSEAMERICAN:ZOM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHEXOHEXOC$0.00C$0.85▼C$4.97C$38.72M2.13253,024 shs72,643 shsMPHMedicureC$1.10C$1.14C$0.85▼C$1.43C$11.48M0.6152652,796 shs7,066 shsVIRVir Biotechnology$9.19$9.50$4.16▼$11.66$1.55B1.71.53 million shs1.21 million shsZOMZomedica$0.00$0.09▼$0.16$95.35M1.034.72 million shs790,936 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHEXOHEXO0.00%0.00%0.00%0.00%0.00%MPHMedicure0.00%-7.56%+22.22%-0.90%+17.02%VIRVir Biotechnology0.00%+4.79%-11.38%-3.16%+104.22%ZOMZomedica0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHEXOHEXOC$0.00C$0.85▼C$4.97C$38.72M2.13253,024 shs72,643 shsMPHMedicureC$1.10C$1.14C$0.85▼C$1.43C$11.48M0.6152652,796 shs7,066 shsVIRVir Biotechnology$9.19$9.50$4.16▼$11.66$1.55B1.71.53 million shs1.21 million shsZOMZomedica$0.00$0.09▼$0.16$95.35M1.034.72 million shs790,936 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHEXOHEXO0.00%0.00%0.00%0.00%0.00%MPHMedicure0.00%-7.56%+22.22%-0.90%+17.02%VIRVir Biotechnology0.00%+4.79%-11.38%-3.16%+104.22%ZOMZomedica0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHEXOHEXO 0.00N/AN/AN/AMPHMedicure 0.00N/AN/AN/AVIRVir Biotechnology 2.89Moderate Buy$20.25120.35% UpsideZOMZomedica 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MPH, HEXO, VIR, and ZOM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026VIRVir Biotechnology Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$23.004/10/2026VIRVir Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/4/2026VIRVir Biotechnology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.002/26/2026VIRVir Biotechnology Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$20.00(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHEXOHEXOC$124.10M0.00N/A1.55C$3.24 per share0.00MPHMedicureC$28.86M0.40C$0.44 per share2.49C$1.21 per share0.91VIRVir Biotechnology$68.56M22.61N/AN/A$4.82 per share1.91ZOMZomedica$25.19M0.00N/AN/A$0.24 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHEXOHEXO-C$273.18M-C$3.41N/AN/A-220.13%-106.39%-14.96%N/AMPHMedicure-C$2.03M-C$0.68N/AN/AN/A-21.74%-44.51%-5.63%N/AVIRVir Biotechnology-$437.99M-$3.13N/AN/AN/A-638.88%-53.31%-41.76%8/5/2026 (Estimated)ZOMZomedica-$34.53M-$0.06N/AN/AN/A-232.88%-12.47%-11.84%N/ALatest MPH, HEXO, VIR, and ZOM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026VIRVir Biotechnology-$0.01-$0.85-$0.84-$0.85$55.49 million($0.03) millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHEXOHEXON/AN/AN/AN/AN/AMPHMedicureN/A2.24%N/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/AZOMZomedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHEXOHEXO125.990.410.40MPHMedicure6.341.041.29VIRVir BiotechnologyN/A7.117.11ZOMZomedicaN/A10.8210.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHEXOHEXO7.57%MPHMedicure4.85%VIRVir Biotechnology65.32%ZOMZomedica8.95%Insider OwnershipCompanyInsider OwnershipHEXOHEXO3.03%MPHMedicure26.68%VIRVir Biotechnology2.90%ZOMZomedica4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHEXOHEXO69044.00 millionN/ANot OptionableMPHMedicureN/A10.44 millionN/ANot OptionableVIRVir Biotechnology580168.65 million163.76 millionOptionableZOMZomedica50979.95 million938.89 millionNot OptionableMPH, HEXO, VIR, and ZOM HeadlinesRecent News About These CompaniesZomedica Pharmaceuticals (ZOMDF) SEC FilingsMay 23 at 11:25 PM | nasdaq.comZomedica Corp.: Zomedica Announces "Fifth Friday at Four" Webinar on May 29th: First Quarter 2026 Financial Results and a Deep Dive into the Companion Animal VetTech MarketMay 15, 2026 | finanznachrichten.deZomedica Corp.: Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in LiquidityMay 6, 2026 | finanznachrichten.deZomedica Corp. (ZOMDF) Discusses Manufacturing Strategy and Quality Operations for Veterinary Diagnostics and Therapeutics TranscriptApril 24, 2026 | seekingalpha.comZomedica Insider Trading Activity | OTC:ZOMDF | BenzingaApril 7, 2026 | benzinga.comZomedica Corp. (ZOMDF) Discusses the Equine Veterinary Market Opportunity TranscriptMarch 28, 2026 | seekingalpha.comZomedica Corp.: Zomedica Announces Strategic Collaboration with Boehringer Ingelheim to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA PlatformMarch 19, 2026 | finanznachrichten.deZomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and ...March 16, 2026 | pharmiweb.comPZomedica Corp.: Zomedica to Review 2025 Financial Results and Highlight Equine Market Opportunity During March 27th "Fourth Friday at Four" Investor WebinarMarch 10, 2026 | finanznachrichten.deZomedica Corp. (ZOMDF) Discusses R&D Strategy and Innovation in Veterinary Diagnostic and Therapeutic Technologies TranscriptFebruary 27, 2026 | seekingalpha.comZomedica Corp.: Zomedica Expands Distribution of TRUVIEW Digital Microscopy Platform Through National Agreement with Moichor, a Leader in Veterinary PathologyFebruary 25, 2026 | finanznachrichten.deZomedica Corp.: Zomedica Announces "Fourth Friday at Four" Webinar on February 27th Focused on Research & Development and Its Innovation PipelineFebruary 5, 2026 | finanznachrichten.deZomedica Corp. (ZOMDF) Discusses Technology and Digital Innovation Driving Growth in Animal Health TranscriptJanuary 23, 2026 | seekingalpha.comZomedica Corp.: Zomedica Expands its TRUVIEW Microscopy Platform with AI Diagnostic Interpretation, Growing its Market OpportunityJanuary 23, 2026 | finanznachrichten.deZomedica Corp.: Zomedica Announces "Fourth Friday at Four" Webinar on January 23rd Focused on Digital Innovation & Technology-Driven GrowthJanuary 14, 2026 | finanznachrichten.deModern therapies for patients with chronic painDecember 16, 2025 | dvm360.comDZomedica Corp. (ZOMDF) Q3 2025 Earnings Call TranscriptNovember 21, 2025 | seekingalpha.comFull-body therapy bed is launched for pain management and mobility supportOctober 24, 2025 | dvm360.comDZomedica Corp.: Zomedica Announces Launch of the Assisi Loop Lounge, Scientifically Backed tPEMF Therapy for PetsOctober 23, 2025 | finanznachrichten.deZomedica Corp.: Zomedica Expands TRUFORMA Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate AssaySeptember 23, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Pipelines and Automation: 2 Energy Plays Built for Any Oil PriceBy Chris Markoch | April 26, 2026The Volatility Harvester That Thrives in Market ChaosBy Peter Frank | April 27, 2026MPH, HEXO, VIR, and ZOM Company DescriptionsHEXO TSE:HEXOHEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada.Medicure CVE:MPHC$1.10 0.00 (0.00%) As of 05/22/2026 10:37 AM EasternMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.Vir Biotechnology NASDAQ:VIR$9.19 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$9.18 0.00 (-0.05%) As of 05/22/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.Zomedica NYSEAMERICAN:ZOMZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
